{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/theophylline/","result":{"pageContext":{"chapter":{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline","depth":2,"htmlHeader":"<!-- begin field 673f7884-2f0e-447d-b672-a6d7016c014b --><h2>Theophylline</h2><!-- end field 673f7884-2f0e-447d-b672-a6d7016c014b -->","summary":"","htmlStringContent":"<!-- begin item b3de6f3f-00cd-4aee-af3c-a6d7016bfc35 --><!-- end item b3de6f3f-00cd-4aee-af3c-a6d7016bfc35 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e401f568-c894-56df-8c31-4cb7f9c962dd","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 75dd1359-a62c-44db-a45e-a6f700ed2168 --><h3>Which dose should be given?</h3><!-- end field 75dd1359-a62c-44db-a45e-a6f700ed2168 -->","summary":"","htmlStringContent":"<!-- begin item e221ba2a-d7b0-437a-b49a-a6f700ed2055 --><!-- begin field 62f41d46-b8dd-4fc4-8c43-a6f700ed2168 --><ul><li><strong>Theophylline can be used as an add-on therapy in the treatment of asthma.</strong></li><li>Theophylline is taken orally and all available brands are modified release preparations.</li><li><strong>When prescribing theophylline, the brand should be specified on the prescription.</strong> Because of differences in bioavailability among brands, people should be maintained on the same brand of theophylline.</li><li><strong>Doses are as follows:</strong><ul><li>Nuelin SA<sup>® </sup>175 tablets — 175 mg to 350 mg every 12 hours in adults and children aged 12 years and over, 175 mg every 12 hours in children aged 6 to 11 years.</li><li>Nuelin SA<sup>® </sup>250 tablets — 250 mg to 500 mg every 12 hours in adults and children aged 12 years and over, 125 mg to 250 mg every 12 hours in children aged 6 to 11 years.</li><li>Slo-Phyllin<sup>®</sup> capsules — 250 mg to 500 mg every 12 hours in adults and children aged 12 years and over, 125 mg to 250 mg every 12 hours in children aged 6 to 11 years, 60 mg to 120 mg every 12 hours in children aged 2 to 5 years.</li><li>Uniphyllin Continus<sup>®</sup> tablets —200 mg every 12 hours, titrated to a maximum of 400 mg in adults and children aged 12 years and over, 9 mg/kg every 12 hours, titrated to a maximum of 200 mg per dose in children aged 2 to 11 years. In some children with chronic asthma, doses can be increased to 10-16 mg/kg every 12 hours, titrated to a maximum of 400 mg per dose. <ul><li>Consider prescribing a larger evening or morning dose to achieve optimum therapeutic effect when symptoms are most severe.</li><li>In people not currently receiving theophylline whose night-time or daytime symptoms persist despite other treatment, the total daily requirement may be given as a single evening or morning dose.</li></ul></li></ul></li><li><strong>Before starting theophylline, check:</strong><ul><li>Urea and electrolyte levels (paying particular attention to potassium levels).</li><li>Liver function.</li></ul></li><li><strong>In most individuals, a plasma-theophylline concentration of 10–20 mg/litre (55–110 micromol/litre) is required for satisfactory bronchodilation</strong>, although a lower plasma-theophylline concentration of 5–15 mg/litre may be effective. Adverse effects can occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.</li><li><strong>Check drug plasma levels:</strong><ul><li>Five days after starting oral treatment.</li><li>Routinely every 6–12 months. Check more regularly in older people or those with heart failure or hepatic impairment.</li><li>At least 3 days after any dose adjustments.</li><li>If an enzyme-inhibiting drug (such as erythromycin, clarithromycin, allopurinol, or cimetidine) is prescribed (raises plasma levels) or if an enzyme-inducing drug (such as carbamazepine, rifampicin, or St John's Wort) is prescribed (lowers plasma levels).</li><li>If the person starts or stops smoking — a dose adjustment may be needed because tobacco can lower the plasma levels of theophylline.</li></ul></li><li><strong>Check potassium levels regularly in people taking theophylline alongside beta-2 agonists, corticosteroids, or diuretics, and in all people with severe asthma.</strong> Plasma potassium concentrations may be reduced by beta-2 agonists, corticosteroids, and diuretics. This effect may be potentiated by theophylline, and further exacerbated by hypoxia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">London and South East Medicines Information Service et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 62f41d46-b8dd-4fc4-8c43-a6f700ed2168 --><!-- end item e221ba2a-d7b0-437a-b49a-a6f700ed2055 -->","subChapters":[]},{"id":"fdc4ec0d-ed2b-515f-8c51-e2a2517a989e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 772be6f2-c788-42be-8211-a6da0175bc1e --><h3>Contraindications and cautions</h3><!-- end field 772be6f2-c788-42be-8211-a6da0175bc1e -->","summary":"","htmlStringContent":"<!-- begin item 00f6def4-a536-422a-b46e-a6da0175b4ba --><!-- begin field 560849bf-d1ce-4715-8c64-a6da0175bc1e --><ul><li><strong>Do not prescribe theophylline to:</strong><ul><li>People with porphyria.</li><li>People with hypersensitivity to xanthines.</li><li>Children concomitantly receiving ephedrine.</li><li>Infants under 6 months of age.</li></ul></li><li><strong>Use theophylline with caution in people with:</strong><ul><li>Cardiovascular disease, including cardiac arrhythmias.</li><li>Hepatic impairment.</li><li>Hyperkalaemia risk.</li><li>Hypertension.</li><li>Hyperthyroidism.</li><li>Peptic ulcers.</li><li>Epilepsy.</li></ul></li><li><strong>Fever decreases the clearance of theophylline.</strong> It may be necessary to decrease the dose in people with acute febrile illness to avoid intoxication.</li><li><strong>The half-life of theophylline may be prolonged in older people, and in those with heart failure, or hepatic impairment.</strong> A reduction in dosage may be necessary to avoid toxic accumulation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 560849bf-d1ce-4715-8c64-a6da0175bc1e --><!-- end item 00f6def4-a536-422a-b46e-a6da0175b4ba -->","subChapters":[]},{"id":"1712f9ce-1a6c-53c1-b8c5-caf02dd40ca8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d475ca26-c87d-44d7-8881-a6da0175edd0 --><h3>Adverse effects</h3><!-- end field d475ca26-c87d-44d7-8881-a6da0175edd0 -->","summary":"","htmlStringContent":"<!-- begin item 7f7a7b1b-16bb-4fb6-96a2-a6da0175e626 --><!-- begin field d55c37ff-7a73-493d-9cdf-a6da0175edd0 --><ul><li>The adverse effects of theophylline include nausea (most common), vomiting, tremor, headache, central nervous system stimulation, insomnia, palpitations, arrhythmias, and convulsion (rare).</li><li>Adverse effects can occur with plasma theophylline concentrations of 10 mg/L to 20 mg/L. However, a plasma concentration in this range is required in most people to achieve a satisfactory clinical effect.</li><li>Both the frequency and severity of adverse effects increase when plasma concentrations of theophylline is above 20 mg/L.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field d55c37ff-7a73-493d-9cdf-a6da0175edd0 --><!-- end item 7f7a7b1b-16bb-4fb6-96a2-a6da0175e626 -->","subChapters":[]},{"id":"0a4c7bc3-f324-5b48-ad34-a1d187a34bb0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5f705f3c-ecf5-4240-91cc-a6da017619d0 --><h3>Drug interactions</h3><!-- end field 5f705f3c-ecf5-4240-91cc-a6da017619d0 -->","summary":"","htmlStringContent":"<!-- begin item e70d47e7-baba-4afa-8066-a6da01761270 --><!-- begin field e0b549e5-b592-4d95-ac25-a6da017619d0 --><ul><li><strong>The key drug interactions with theophylline include:</strong><ul><li><strong>Beta-2 agonists, corticosteroids, diuretics</strong> — hypokalaemia may be potentiated.<ul><li>Check serum potassium levels regularly.</li></ul></li><li><strong>Lithium</strong> — excretion of lithium may be potentiated.<ul><li>Check plasma lithium levels and alter dose if necessary.</li></ul></li><li><strong>Fluvoxamine</strong> — can raise the plasma level of theophylline.<ul><li>Avoid concomitant use if possible, or halve the theophylline dose and monitor plasma levels.</li></ul></li><li><strong>Plasma levels of theophylline can be altered by concomitant use with liver enzyme-inhibiting drugs</strong> such as verapamil, ciprofloxacin, fluconazole, erythromycin, clarithromycin, allopurinol, or cimetidine, or liver enzyme-inducing drugs such as primidone, phenobarbital, carbamazepine, phenytoin, ritonavir, rifampicin, or St John's Wort.<ul><li>Check drug plasma levels if any of these are used concomitantly.</li></ul></li></ul></li><li>The person should be made aware that over-the-counter cough and decongestant preparations that contain theophylline (such as Do-Do Chesteze<sup>®</sup>, Franol<sup>®</sup>, and Franol Plus<sup>®</sup>) should be avoided.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field e0b549e5-b592-4d95-ac25-a6da017619d0 --><!-- end item e70d47e7-baba-4afa-8066-a6da01761270 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}